Cyrille J. Cohen

Centre for Human Genetics — United Kingdom

Medicine · Health Sciences

33h-index6.3kcitations110works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(64), Immunotherapy and Immune Responses(47), Immune Cell Function and Interaction(23), Cancer Immunotherapy and Biomarkers(15), Virus-based gene therapy research(14)

Publications109 total

Supplementary Table 1 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
2025Open Access
Supplementary Figures S1-S7 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
2025Open Access
Supplementary Data 1 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
2025Open Access
Summary analysis of the phase 1a/b study with HBI0101, an academic anti-BCMA chimeric antigen receptor T-cell (CART) for relapsed/refractory multiple myeloma
Blood·2025Open Access
RNA splicing dynamics in CD8 T cells uncovers isoforms that impact T cell-mediated cancer immunotherapy
2025Open Access
POS0694 DISSECTING THE GENETIC AND FUNCTIONAL ASSOCIATION OF CARD9 WITH AXIAL SPONDYLOARTHRITIS
Annals of the Rheumatic Diseases·2025Open Access
Potentiating T cell tumor targeting using a combination of TCR with a Siglec-7 based CSR
Frontiers in Immunology·2025Open Access
An Aged Microenvironment Increases CAR T Cell Cytotoxicity but Impairs Therapeutic Efficacy
2025Open Access
Hexokinase2-engineered T cells display increased anti-tumor function
Frontiers in Immunology·2025· 4 citedOpen Access
Efficacy and Safety of Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis
Journal of Clinical Oncology·2024· 14 cited
Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis
Blood·2024· 2 citedOpen Access
Efficacy of HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma
Blood·2024· 3 citedOpen Access
Targeting TGFβ with chimeric switch receptor and secreted trap to improve T cells anti-tumor activity
Frontiers in Immunology·2024· 4 citedOpen Access
Figure S4 from Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells
2024Open Access
Data from Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells
2024Open Access
Figure S1 from Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells
2024Open Access
Figure S3 from Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells
2024Open Access
Figure S2 from Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells
2024Open Access
OA-34 HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2024
Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells
Cancer Immunology Research·2024· 8 cited
page 1 of 6Next →

Frequent Co-authors

Steven A. Rosenberg(17), Zhili Zheng(9), Katerina Shamalov(9), Richard A. Morgan(8), Miryam Horovitz‐Fried(8), Yangbing Zhao(7), Paul F. Robbins(6), Richard A. Morgan(5), Tilda Barliya(5), Vasyl Eisenberg(4), Maria R. Parkhurst(4), Chen Ankri(4), Nicholas P. Restifo(4), Rinat Meir(4), Menachem Motiei(4), Rachela Popovtzer(4), Shiran Hoogi(4), Shlomit Kfir‐Erenfeld(4), Nathalie Asherie(4), Miri Assayag(4)